July 12, 2018
Wasdell Group launch serialisation service
The Wasdell Group (Wasdell) has launched its serialisation service ahead of the EU FMD and US DSCSA implementation deadlines.
Pharmaceuticals, Biotechnology and Life Sciences
Category: news
July 12, 2018
NICE backs EUSA Pharma’s Qarziba for children with high-risk neuroblastoma
The National Institute for Health and Care Excellence (NICE) has recommended the use of the EUSA Pharma’s targeted cancer immunotherapy, QARZIBA…
July 10, 2018
Myocant Sciences complets screening patients for heavy menstrual bleeding study
Myovant Sciences has completed screening patients for its LIBERTY 1 study, the first of two Phase 3 replicate studies evaluating…
July 2, 2018
Alvogen, Prestige BioPharma in Hervelous selling deal for Central and Eastern Europe
Alvogen and Prestige BioPharma have entered into a deal for the exclusive partnership and supply for the commercialization of Prestige…
July 2, 2018
AstraZeneca’s lung cancer drug approved in Japan
AstraZeneca and MedImmune, its global biologics research and development arm, today announced that the Japanese Ministry of Health, Labour and…
June 29, 2018
CHMP recommends approval of Sanofi’s Cablivi
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended approval of Cablivi (caplacizumab) in Europe…
June 29, 2018
Novartis aims at spinoff of Alcon eye care devices business
Novartis on Friday said it intends to spinoff Alcon, its eye care division, into a separately-traded standalone company, which would…
June 28, 2018
Sanofi and Advent in negotiations for €1.9 billion acquisition of Zentiva
Sanofi and Advent International have finished negotiations for the acquisition of Zentiva, Sanofi’s European generics business, by Advent and the…
June 28, 2018
Better prevention can curbe significant disruption to daily life and work caused by migraine
Novartis and the European Migraine and Headache Alliance (EMHA) Wednesday presented initial findings from the largest global migraine patient study…
June 27, 2018
Lynparza significantly delays disease progression in Phase III 1st-line SOLO-1 trial for ovarian cancer
AstraZeneca and Merck’s Phase III SOLO-1 trial of Lynparza (olaparib) tablets, for women with BRCA-mutated (BRCAm) advanced ovarian cancer treated…